142 related articles for article (PubMed ID: 14709627)
1. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.
Stresser DM; Broudy MI; Ho T; Cargill CE; Blanchard AP; Sharma R; Dandeneau AA; Goodwin JJ; Turner SD; Erve JC; Patten CJ; Dehal SS; Crespi CL
Drug Metab Dispos; 2004 Jan; 32(1):105-12. PubMed ID: 14709627
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
3. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
Chang SY; Chen C; Yang Z; Rodrigues AD
Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
5. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes.
Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL
Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
[TBL] [Abstract][Full Text] [Related]
7. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
8. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
10. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
Lillibridge JH; Liang BH; Kerr BM; Webber S; Quart B; Shetty BV; Lee CA
Drug Metab Dispos; 1998 Jul; 26(7):609-16. PubMed ID: 9660842
[TBL] [Abstract][Full Text] [Related]
14. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
15. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N
Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.
Li X; Song X; Kamenecka TM; Cameron MD
Drug Metab Dispos; 2012 Sep; 40(9):1803-9. PubMed ID: 22696420
[TBL] [Abstract][Full Text] [Related]
17. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo Z; Raeissi S; White RB; Stevens JC
Drug Metab Dispos; 1997 Mar; 25(3):390-3. PubMed ID: 9172960
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate.
Kim JY; Baek M; Lee S; Kim SO; Dong MS; Kim BR; Kim DH
Drug Metab Dispos; 2001 Dec; 29(12):1555-60. PubMed ID: 11717174
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro.
Iwase M; Kurata N; Ehana R; Nishimura Y; Masamoto T; Yasuhara H
Hum Exp Toxicol; 2006 Dec; 25(12):715-21. PubMed ID: 17286149
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
